Skip to main content
. 2020 Nov 18;22(Suppl L):L77–L81. doi: 10.1093/eurheartj/suaa140

Figure 1.

Figure 1

In PARAMAOUNT trial11 performed in heart failure with preserved ejection fraction subjects, sacubitril–valsartan administration was followed by reduction of NT pro-BNP after 4 weeks treatment that became statistically significant after 12 week of therapy and was sustained to 36 weeks, though the between group difference was no longer significant because valsartan treated group displayed a delayed NT-proBNP decline.